Posts by Muana Minkoué
The HES-SO Valais-Wallis Institute of Informatics will lead a European project
The Institute of Informatic’s eHealth research cluster has been awarded scientific coordination of the European Hereditary project. The project aims to revolutionise disease detection, plan treatment response and explore medical knowledge of neurodegenerative diseases such as Parkinson and Alzheimer. Hereditary innovates by integrating heterogeneous semantic data to analyse the interactions between the brain…
Read MoreSpineart successfully raised a CHF20 Million convertible financing
Spineart secures more than CHF 20 Million in convertible financing following completion of BAGUERA® C IDE studies enrolment. The funding comes on the heels of the completion of enrolment in the two BAGUERA® C IDE studies, underlining Spineart’s commitment to advancing spinal surgery through large-scale investments in research and development. More than CHF…
Read MoreGGBA 2023 report confirms Western Switzerland’s appeal to foreign companies
17 foreign companies have joined the Swiss Health Valley in 2023, with the prospect of creating more than 150 jobs in the next three years. Founded in 2010, Greater Geneva Bern area (GGBa) brings together the cantons of Bern, Fribourg, Vaud, Neuchâtel, Geneva and Valais. GGBa’s mission is to attract foreign companies that…
Read MoreLonza acquires a new manufacturing site in the US
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced the signing of an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 Billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract…
Read MoreResearchers based in Switzerland can once again apply for ERC grants
As negotiations between the EU and Switzerland have been officially launched today, researchers based in Switzerland can now once again apply for ERC grants. This follows the adoption of the Swiss and EU negotiating mandates on 8 and 12 March 2024 respectively. The two mandates authorise Switzerland and the Commission to negotiate the…
Read MoreAlithea Genomics closes CHF 2.8 Million in seed financing extension
This milestone marks a significant step forward in the company’s journey to revolutionise large-scale RNA sequencing and transcriptomics. Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing. The round was led by…
Read MorePeriVision announces FDA registration for its medical software VisionOne™
PeriVision, proudly announces its recent FDA registration for its first medical software product VisionOne. This significant milestone marks a pivotal moment in PeriVision’s mission to enhance patient care and revolutionise the field of ophthalmology. With VisionOne, ophthalmologists and optometrists can easily configure eye tests on portable VR headsets and subsequently analyse the results…
Read MorePristem affordable radiology thrives in South Africa
A few months ago, Pristem’s South African subsidiary opened its first state-of-the-art, affordable radiology center in the township of Alexandra. The Swiss medtech is due to open a second one in Soweto this month, and has big plans for the future. Through its Open Diagnostics brand, Pristem is on a mission to provide…
Read MoreUS FDA grants Orphan Drug Designation for iOnctura’s Autotaxin cancer therapy
iOnctura’s autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer gets Orphan Drug Designation (ODD) by the US FDA. IOnctura is a pioneering clinical-stage biotechnology company developing transformative cancer therapies. After assessing its novel chemical and biological properties including an attractive non-clinical safety and efficacy profile, the US Food and Drug Administration (FDA) has…
Read MoreDebiopharm launches expansion of WEE1 inhibitor
Debiopharm aims to further characterise the safety, tolerability, and preliminary anti-tumour activity of its potent WEE1 inhibitor Debio 0123 as monotherapy in three different expansion cohorts. Debiopharm announced the first patient dosed in the expansion of its open-label, non-randomised, multicenter Phase 1 study evaluating Debio 0123, an oral, potent, highly selective and…
Read More